CPT code 80177: Levetiracetam level, quantitative concentration2026 Medicare lab fee · Clinical Laboratory Fee Schedule
A quantitative levetiracetam concentration test supports medication monitoring in patients treated for epilepsy when seizure control, adverse effects, or treatment changes prompt evaluation.
Medicare pays $13.25 for 80177 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$13.25
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2020
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 7 sections
What 80177 covers
This assay measures levetiracetam concentration for therapeutic drug monitoring in patients treated for epilepsy. Neurologists and other clinicians may order it when evaluating breakthrough seizures, suspected adverse effects, adherence concerns, or a change in clinical status or dosing. Results are considered with seizure control, dose timing, renal function, and the patient’s clinical course; a concentration alone does not establish whether treatment is effective.
Report 80177 for levetiracetam, not another antiseizure medication. When monitoring includes multiple drugs, report each measured analyte with its corresponding assay code. Medicare pays 80177 through the CLFS at one national amount across all localities, with no office-versus-facility difference. The 2026 national amount is $13.25, unchanged from 2020 through 2026. The test is paid through the CLFS and excluded from the physician fee schedule.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 80177
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 80177. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 80177 with status X (excluded by statute), so the test itself is paid only from the CLFS.
80177 on the lab fee schedule since 2020
80177 · CLFS 2026 Q4 (current)
$13.25
Unchanged since Jan 1, 2020
27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.
80177 compared with similar tests
- 80175Lamotrigine levelQuantitative drug assay$13.25
- 80175 measures lamotrigine, not levetiracetam. Select the code for the medication whose concentration the laboratory measures.
- 80183Oxcarbazepine levelQuantitative concentration assay$13.25
- 80183 is for an oxcarbazepine-related drug measurement. It does not report a levetiracetam concentration.
- 80185Phenytoin levelTotal drug concentration$13.25
- 80185 measures total phenytoin. Use 80177 for levetiracetam and 80185 for total phenytoin when both are tested.
80177 billing questions
When should 80177 be selected instead of another antiseizure drug assay?
Use 80177 when the test measures levetiracetam. Choose the assay code for the different drug when another antiseizure medication is being measured.
Can 80177 be reported with another antiseizure medication level?
Yes, when the clinician orders separate drug measurements, each assay is reported for its own analyte. For example, levetiracetam and lamotrigine levels use separate codes.
What should the record support for 80177?
The order and record should identify levetiracetam monitoring and the clinical reason, such as breakthrough seizures, suspected adverse effects, or a treatment change.
How does Medicare pay for 80177?
Medicare pays 80177 under the CLFS. The same national amount applies across localities and in office and facility settings.
Is 80177 paid under the physician fee schedule?
No. Medicare payment for this laboratory test is through the CLFS; the test is excluded from the physician fee schedule.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 80177 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist